Close

Ocugen, Inc. (OCGN) PT Lowered to $4.50 at Chardan Capital Markets

Go back to Ocugen, Inc. (OCGN) PT Lowered to $4.50 at Chardan Capital Markets

Ocugen Inc. Announces Michael Shine as Senior Vice President, Commercial

June 10, 2021 7:35 AM EDT

MALVERN, Pa., June 10, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN), a biopharmaceutical company focused on discovering, developing, and commercializing gene therapies to cure blindness diseases and developing a vaccine to save lives from COVID-19, today announced that Michael Shine will be joining Ocugen as Senior Vice President, Commercial.

Michael Shine is a pharmaceutical and biotechnology executive with nearly 35 years of industry experience. Over the course of his career, Mr.... More

Ocugen to pursue a BLA path in the US for its COVID-19 vaccine candidate

June 10, 2021 7:30 AM EDT

Company intends to work with the FDA towards filing a Biologics License Application (BLA) in the USCompany to engage with Health Canada to seek authorization under Interim Order for use in Canada

MALVERN, Pa., June 10, 2021 (GLOBE NEWSWIRE) -- Ocugen, Inc. (NASDAQ: OCGN) (Company), a biopharmaceutical company focused on discovering,... More